BridgeBio Pharma (BBIO) Akcie Kurz
BridgeBio Pharma Kurz
Tržby rostly o 52,1 % ročně za posledních 6 let na 502,08 Mil. USD. čistá marže společnosti BridgeBio Pharma je nyní -145,3 %, nahoru z -806,9 % před několika lety. Medián cílové ceny analytiků je 107,00 USD, tedy nad aktuální cenu o 40,7 %. Z 29 analytiků jich 26 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie BridgeBio Pharma
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model BridgeBio Pharma a analýza akcií
Nejčastější otázky týkající se akcie BridgeBio Pharma
BridgeBio Pharma Inc is a biopharmaceutical company specializing in the development and commercialization of genetic medicines. The company aims to identify and advance therapies for diseases with clear genetic causes, leveraging its deep understanding of molecular pathways and human biology. BridgeBio Pharma Inc follows a diversified business model, which includes creating subsidiary companies focused on developing treatments for specific genetic diseases. These subsidiaries collaborate with academic institutions and industry partners to expedite the development of innovative therapies. By focusing on genetically driven diseases and utilizing a collaborative approach, BridgeBio Pharma Inc strives to bring transformative treatments to patients in need.
BridgeBio Pharma Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of BridgeBio Pharma Inc in the market include companies such as Amgen Inc, Gilead Sciences Inc, Biogen Inc, and Vertex Pharmaceuticals Incorporated.
BridgeBio Pharma Inc is a leading pharmaceutical company specializing in the development and commercialization of targeted therapies for genetic diseases and cancers. Founded in 2015, BridgeBio Pharma Inc has rapidly grown into a prominent player in the biotechnology industry. The company's mission is to identify and advance transformative medicines that address the unmet needs of patients with genetically driven conditions. With its innovative pipeline of candidates, BridgeBio Pharma Inc aims to make a meaningful impact on patients' lives. By leveraging its deep expertise in genetics and drug development, the company is poised to revolutionize the treatment landscape for various rare diseases and oncology indications.
BridgeBio Pharma Inc has achieved several significant milestones since its inception. The company has successfully developed a diverse pipeline of investigative compounds across multiple therapeutic areas, including genetically defined diseases and cancers. BridgeBio Pharma has also formed strategic partnerships with leading pharmaceutical companies to accelerate the development and commercialization of its promising candidates. Additionally, the company has received regulatory approvals for several of its therapeutics and has successfully advanced them into clinical trials. These milestones highlight BridgeBio Pharma's commitment to addressing unmet medical needs and advancing innovative therapies for patients around the world.
BridgeBio Pharma Inc is primarily present in the United States.
BridgeBio Pharma Inc represents a commitment to innovative solutions and transformative therapies. Guided by a strong corporate philosophy, the company focuses on addressing unmet medical needs and improving patient outcomes. BridgeBio Pharma Inc pioneers in developing targeted medicines for genetic diseases and cancers. With their dedication to scientific excellence, they identify potential drug candidates and accelerate their development through collaborations and partnerships. By leveraging cutting-edge research and technological advancements, BridgeBio Pharma Inc aims to positively impact the lives of patients and families affected by rare genetic disorders.
Analytici aktuálně stanovují průměrnou cílovou cenu 110,18 USD pro akcii BridgeBio Pharma (medián: 107,00 USD), tedy +44,9 % vůči poslední ceně. Konsensus vychází z 29 hodnocení analytiků.
29 analytiků aktuálně hodnotí akcii BridgeBio Pharma: 26 doporučuje koupit, 3 držet a 0 prodat. Pro rok 2026 analytici očekávají u BridgeBio Pharma tržby 1,09 Mld. USD a zisk na akcii -2,62 USD.
Při aktuálním kurzu se akcie BridgeBio Pharma obchoduje za 69,24 EUR (76,03 USD).
Akcie BridgeBio Pharma (BBIO) je kótována na 3 burzách, mimo jiné: NASDAQ (BBIO), München (2CL.MU), Düsseldorf (2CL.DU).
BridgeBio Pharma Inc. is a biotechnology company focused on developing drugs for rare diseases. The company was founded in 2015 and is based in Palo Alto, California. Its business model is based on identifying and developing therapy approaches for rare diseases. BridgeBio works closely with researchers, academics, and other biotech companies to develop innovative therapies. It has a strong pipeline of drug candidates in preclinical and clinical studies. Flagship products include Infigratinib for FGFR2-gene defined cholangiocarcinoma and BBP-265 for ACADVL deficiency. BridgeBio has partnerships with major pharmaceutical companies such as Pfizer and Roche. It focuses on rare diseases, taking advantage of the limited treatment options and strong need in these patient populations. The company is funded through investments from venture capital firms and public institutions. It had a successful IPO in June 2019, raising nearly $350 million for pipeline development and financing teams working on new therapies. Overall, BridgeBio's business model is centered on identifying and developing therapies for rare diseases, with a strong pipeline and partnerships in place.
Tržby očekávané za BridgeBio Pharma činí 1,09 Mld. USD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za BridgeBio Pharma činí -516,10 Mil. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) BridgeBio Pharma je aktuálně -29,06. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie BridgeBio Pharma.
Poměr ceny k tržbám (P/S) BridgeBio Pharma je aktuálně 13,76. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie BridgeBio Pharma.
Score kvality pro BridgeBio Pharma je 5/10.
ISIN BridgeBio Pharma je US10806X1028. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN BridgeBio Pharma je A2PLX7. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker BridgeBio Pharma je BBIO. Symbol tickeru se používá k obchodování akcií BridgeBio Pharma na burze.
BridgeBio Pharma akcie
BridgeBio Pharma Peer Group
BridgeBio Pharma Ticker
BridgeBio Pharma FIGI
Všechny fundamentální údaje o BridgeBio Pharma v podrobné analýze
Naše analýzy akcií společnosti BridgeBio Pharma zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti BridgeBio Pharma. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: